Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-09-01
|
Subgam®VF |
primary immune deficiency disorders, common variable immunodeficiency, X-linked agammaglobulinaemia, hyperimmunoglobulin M syndrome |
3 |
Bio Products Laboratory (UK) |
Immunological diseases |
2015-09-01
|
VM202 |
chronic non-healing ischemic diabetic foot ulcers |
3 |
ViroMed (Republic of Korea) |
Cardiovascular diseases - Metabolic diseases |
2015-09-01
|
cetux-CAR T cells, nimo-CAR T cells |
|
preclinical |
Ziopharm Oncology (USA - MA) |
Cancer - Oncology |
2015-09-01
|
HS-110 (viagenpumatucel-L) and nivolumab |
non-small cell lung cancer (NSCLC) |
1b |
Heat Biologics (USA - NC) |
Cancer - Oncology |
2015-08-31
|
CicloMulsion® cremophor-free IV cyclosporine formulation |
myocardial infarction |
3 |
NeuroVive Pharmaceutical (Sweden) Hospices Civils de Lyon (France) |
Cardiovascular diseases |
2015-08-31
|
Brilinta® (ticagrelor) |
secondary prevention of atherothrombotic events in patients who had experienced a heart attack |
|
AstraZeneca (UK) |
Cardiovascular diseases |
2015-08-31
|
Dysport® (abobotulinumtoxin A ) |
upper limb spasticity |
3 |
Ipsen (France) |
Neurological diseases - CNS diseases |
2015-08-31
|
finerenone (BAY 94-8862) |
diabetic kidney disease |
3 |
Bayer Healthcare (Germany) |
Kidney diseases - Metabolic diseases - Renal diseases |
2015-08-31
|
PINTA 745 |
patients with end stage renal disease who require maintenance hemodialysis and have protein energy wasting |
1-2 |
Atara Biotherapeutics (USA - CA) |
Kidney diseases - Renal diseases |
2015-08-31
|
BNC101 |
metastatic colon cancer, metastatic pancreatic cancer |
1 |
Bionomics (Australia) |
Cancer - Oncology |
2015-08-30
|
Reolysin® (pelareorep - human reovirus type 3 Dearing strain) |
previously treated advanced or metastatic non-small cell lung cancer |
2 |
Oncolytics Biotech (Canada) NCIC Clinical Trials Group (Canada) |
Cancer - Oncology |
2015-08-27
|
durvalumab (MEDI4736) and tremelimumab or AZD9150 |
diffuse large B-cell lymphoma (DLBCL) |
1 |
AstraZeneca (UK) |
Cancer - Oncology |
2015-08-27
|
daratumumab |
relapsed/refractory multiple myeloma |
1-2 |
Genmab (Denmark) |
Cancer - Oncology |
2015-08-27
|
Opsumit® (macitentan) |
pulmonary arterial hypertension (PAH) |
|
Actelion (Switzerland) |
Rare diseases - Cardiovascular diseases - Autoimmune diseases |
2015-08-27
|
Zydelig® (idelalisib) and ofatumumab |
previously-treated patients with chronic lymphocytic leukemia (CLL) |
3 |
Gilead (USA - CA) |
Cancer - Oncology |
2015-08-26
|
combination of ambrisentan and tadalafil |
pulmonary arterial hypertension (PAH) |
3 |
Gilead (USA - CA) GSK (UK) |
Rare diseases - Cardiovascular diseases |
2015-08-26
|
Victoza® (liraglutide) |
type 1 diabetes |
3 |
Novo Nordisk (Denmark) |
Metabolic diseases |
2015-08-26
|
semaglutide |
type 2 diabetes |
3a |
Novo Nordisk (Denmark) |
Metabolic diseases |
2015-08-26
|
durvalumab (MEDI4736) and tremelimumab |
non-small cell lung cancer (NSCLC) |
3 |
AstraZeneca (UK) |
Cancer - Oncology |
2015-08-26
|
Ibrance® (palbociclib) |
breast cancer |
3 |
Alliance Foundation Trials (USA) Pfizer (USA - NY) |
Cancer - Oncology |